Ziopharm in Supply Agreement with Regeneron to Study Glioblastoma Treatment
November 12 2018 - 7:29AM
Dow Jones News
By Michael Dabaie
Ziopharm Oncology Inc. (ZIOP) said Monday it is in a clinical
supply agreement with Regeneron Pharmaceuticals Inc. (REGN) to
evaluate Ziopharm's Ad-RTS-hIL-12 plus veledimex in combination
with Regeneron's Libtayo to treat patients with recurrent
glioblastoma.
Ziopharm and Regeneron will initiate a Phase 2 study in the
first half of 2019 to measure preliminary safety and efficacy of
Ad-RTS-hIL-12 plus veledimex in combination with Libtayo. Ziopharm
will be responsible for the conduct and costs of the clinical
trial, and Regeneron will supply Libtayo for the study. The
companies potentially could explore additional indications.
Ad-RTS-hIL-12 plus veledimex is an investigational gene therapy
to induce and control the production of human interleukin 12 that
activates the immune system and recruits cancer-fighting T cells
into tumors. Libtayo has been approved in the U.S. to treat
patients with metastatic cutaneous squamous cell carcinoma or
locally advanced CSCC who aren't candidates for curative surgery or
radiation.
Ziopharm shares were up 2% to $2.56 premarket.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 12, 2018 08:14 ET (13:14 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024
